文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Targeted Co-Delivery of siRNA and Methotrexate for Tumor Therapy via Mixed Micelles.

作者信息

Hao Fei, Lee Robert J, Yang Chunmiao, Zhong Lihuang, Sun Yating, Dong Shiyan, Cheng Ziyuan, Teng Lirong, Meng Qingfan, Lu Jiahui, Xie Jing, Teng Lesheng

机构信息

School of Life Sciences, Jilin University, Changchun 130012, China.

College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.

出版信息

Pharmaceutics. 2019 Feb 21;11(2):92. doi: 10.3390/pharmaceutics11020092.


DOI:10.3390/pharmaceutics11020092
PMID:30795589
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6409946/
Abstract

A combination of chemotherapeutic drugs and siRNA is emerging as a new modality for cancer therapy. A safe and effective carrier platform is needed for combination drug delivery. Here, a functionalized mixed micelle-based delivery system was developed for targeted co-delivery of methotrexate (MTX) and survivin siRNA. Linolenic acid (LA) was separately conjugated to branched polyethlenimine (b-PEI) and methoxy-polyethyleneglycol (mPEG). MTX was then conjugated to LA-modified b-PEI (MTX-bPEI-LA) to form a functionalized polymer-drug conjugate. Functionalized mixed micelles (M-MTX) were obtained by the self-assembly of MTX-bPEI-LA and LA-modified mPEG (mPEG-LA). M-MTX had a narrow particle size distribution and could successfully condense siRNA at an N/P ratio of 16/1. M-MTX/siRNA was selectively taken up by HeLa cells overexpressing the folate receptor (FR) and facilitated the release of the siRNA into the cytoplasm. In vitro, M-MTX/siRNA produced a synergy between MTX and survivin siRNA and markedly suppressed survivin protein expression. In tumor-bearing mice, M-MTX/Cy5-siRNA showed an elevated tumor uptake. In addition, M-MTX/siRNA inhibited tumor growth. Immunohistochemistry and a western blot analysis showed a significant target gene downregulation. In conclusion, M-MTX/siRNA was highly effective as a delivery system and may serve as a model for the targeted co-delivery of therapeutic agents.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/0ef13d44eb5e/pharmaceutics-11-00092-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/8647d057fb3f/pharmaceutics-11-00092-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/d5baa496f216/pharmaceutics-11-00092-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/2435e9d80538/pharmaceutics-11-00092-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/bf746228b348/pharmaceutics-11-00092-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/306fc29d0e7d/pharmaceutics-11-00092-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/b9c430b5731e/pharmaceutics-11-00092-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/53b3407d498f/pharmaceutics-11-00092-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/4177e15aa4cb/pharmaceutics-11-00092-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/0ef13d44eb5e/pharmaceutics-11-00092-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/8647d057fb3f/pharmaceutics-11-00092-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/d5baa496f216/pharmaceutics-11-00092-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/2435e9d80538/pharmaceutics-11-00092-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/bf746228b348/pharmaceutics-11-00092-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/306fc29d0e7d/pharmaceutics-11-00092-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/b9c430b5731e/pharmaceutics-11-00092-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/53b3407d498f/pharmaceutics-11-00092-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/4177e15aa4cb/pharmaceutics-11-00092-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed07/6409946/0ef13d44eb5e/pharmaceutics-11-00092-g008.jpg

相似文献

[1]
Targeted Co-Delivery of siRNA and Methotrexate for Tumor Therapy via Mixed Micelles.

Pharmaceutics. 2019-2-21

[2]
Targeted and Efficient Delivery of siRNA Using Tunable Polymeric Hybrid Micelles for Tumor Therapy.

Anticancer Res. 2019-3

[3]
Hybrid micelles containing methotrexate-conjugated polymer and co-loaded with microRNA-124 for rheumatoid arthritis therapy.

Theranostics. 2019-7-9

[4]
Synthesis and characterization of novel P(HEMA-LA-MADQUAT) micelles for co-delivery of methotrexate and Chrysin in combination cancer chemotherapy.

J Biomater Sci Polym Ed. 2018-4-9

[5]
Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice.

J Mater Chem B. 2015-10-21

[6]
The therapeutic effect of methotrexate-conjugated Pluronic-based polymeric micelles on the folate receptor-rich tumors treatment.

Int J Nanomedicine. 2015-6-19

[7]
Orthogonally functionalized nanoscale micelles for active targeted codelivery of methotrexate and mitomycin C with synergistic anticancer effect.

Mol Pharm. 2015-3-2

[8]
9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro.

Int J Pharm. 2009-1-4

[9]
Epidermal growth factor receptor targeted methotrexate and small interfering RNA co-delivery.

J Gene Med. 2018-7-17

[10]
Bacillus-shape design of polymer based drug delivery systems with janus-faced function for synergistic targeted drug delivery and more effective cancer therapy.

Mol Pharm. 2015-4-6

引用本文的文献

[1]
The advancement of siRNA-based nanomedicine for tumor therapy.

Nanomedicine (Lond). 2024

[2]
Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress.

Mol Ther Nucleic Acids. 2024-6-17

[3]
The modulation of local and systemic anti-tumor immune response induced by methotrexate nanoconjugate in murine MC38 colon carcinoma and B16 F0 melanoma tumor models.

Am J Cancer Res. 2023-10-15

[4]
Recent Trends in Nanomedicine-Based Strategies to Overcome Multidrug Resistance in Tumors.

Cancers (Basel). 2022-8-26

[5]
Polyethyleneimine (PEI) as a Polymer-Based Co-Delivery System for Breast Cancer Therapy.

Breast Cancer (Dove Med Press). 2022-4-8

[6]
Development of Multi-Scale X-ray Fluorescence Tomography for Examination of Nanocomposite-Treated Biological Samples.

Cancers (Basel). 2021-9-6

[7]
Preparation of siRNA-PLGA/Fab'-PLGA mixed micellar system with target cell-specific recognition.

Sci Rep. 2021-8-18

[8]
Silencing of HMGA2 by siRNA Loaded Methotrexate Functionalized Polyamidoamine Dendrimer for Human Breast Cancer Cell Therapy.

Genes (Basel). 2021-7-20

[9]
Immunomodulatory potential of anticancer therapy composed of methotrexate nanoconjugate and dendritic cell‑based vaccines in murine colon carcinoma.

Oncol Rep. 2021-3

[10]
Small interfering RNA for cancer treatment: overcoming hurdles in delivery.

Acta Pharm Sin B. 2020-11

本文引用的文献

[1]
Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice.

Theranostics. 2018-7-5

[2]
Targeting survivin for therapeutic discovery: past, present, and future promises.

Drug Discov Today. 2017-5-31

[3]
Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.

Cancer Res. 2017-6-15

[4]
Recent development of synthetic nonviral systems for sustained gene delivery.

Drug Discov Today. 2017-4-18

[5]
Safety of antisense oligonucleotide and siRNA-based therapeutics.

Drug Discov Today. 2017-5

[6]
Polymeric mixed micelles as nanomedicines: Achievements and perspectives.

Eur J Pharm Biopharm. 2017-4

[7]
Preventing and Managing Toxicities of High-Dose Methotrexate.

Oncologist. 2016-12

[8]
Recent progress in development of siRNA delivery vehicles for cancer therapy.

Adv Drug Deliv Rev. 2016-6-25

[9]
Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy.

J Control Release. 2016-4-26

[10]
Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment.

Acta Pharm Sin B. 2015-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索